The DOI matches its Crossref record; 78 of the 81 references it cites were found in a registry or an index.
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Open accessAbstract
In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high levels in lymphoid malignancies. In a model for p185BCR-ABL+ B-acute lymphoid leukemia, we show that CDK6 is part of a transcription complex that induces the expression of the tumor suppressor p16INK4a and the pro-angiogenic factor VEGF-A. This function is independent of CDK6's kinase activity. High CDK6 expression thus suppresses proliferation by upregulating p16INK4a, providing an internal safeguard. However, in the absence of p16INK4a, CDK6 can exert its full tumor-promoting function by enhancing proliferation and stimulating angiogenesis. The finding that CDK6 connects cell-cycle progression to angiogenesis confirms CDK6's central role in hematopoietic malignancies and could underlie the selection pressure to upregulate CDK6 and silence p16INK4a.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, CDK6-specific functions include participating as part of a transcription complex that regulates expression of p16INK4a and VEGF-A[5]”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [5]
In the citing paper
“Moreover, ATP-competitive inhibitors cannot disrupt the scaffolding functions of CDK6, which is important for the transcription function of CDK6 [124, 125].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus
González, S., Klatt, P., Delgado, S., Conde, E., López‐Ríos, F., Sánchez‐Céspedes, M., Méndez, J., Antequera, F., & Serrano, M. (2006) · Nature · doi:10.1038/nature04585 · Cited by 186
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,585
Vascular endothelial growth factor (VEGF) and its receptors
Neufeld, G., Cohen, T., Gengrinovitch, S., & Gluzman‐Poltorak, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,511
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Although p16 is also able to promote oncogene-induced senescence (Campisi, 2012), we failed to obtain any evidence of senescence.”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,711
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature reviews. Cancer · doi:10.1038/35106065 · Cited by 1,510
Self-citationCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Flagged first, then by citations
3 of the 81 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 314
Isabella, S., & Mirunalini, S. (2019) · Breast Cancer · doi:10.1007/s12282-019-00950-x · Cited by 11
Cyclin-Dependent Kinases As Potential Targets for Colorectal Cancer: Past, Present and Future
Manohar, S. M. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0064 · Cited by 11
Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia
Pan, T. S., Wang, S., Feng, H., Xu, J., Zhang, M., Yao, Y., Xu, K., & Niu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1064470 · Cited by 11
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Li, H., Zhang, J., & Xie, Y. (2017) · PubMed Central · Cited by 11
Targeting the cell-cycle machinery for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 12
Park, C., Yun, S. J., Ryu, S. J., Lee, S., Lee, Y., Yoon, Y., & Park, S. C. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0417-1 · Cited by 11
Jiao, X., Sante, G. D., Casimiro, M. C., Tantos, Á., Ashton, A. W., Li, Z., Quach, Y., Bhargava, D. K., Rocco, A. D., Pupo, C., et al. (2024) · Oncogenesis · doi:10.1038/s41389-023-00502-1 · Cited by 10
Oubella, A., Laamari, Y., Hachim, M. E., Byadi, S., Auhmani, A., Morjani, H., Riahi, A., Podlipnik, Č., Rohand, T., Meervelt, L. V., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132573 · Cited by 9
Zhao, Y., Xu, B., Wang, F., Jiang, F., Xu, J., & Yu, D. (2022) · Cancer Medicine · doi:10.1002/cam4.5260 · Cited by 9
Wang, A., Ji, Z., Xuan, R., Zhao, X., Hou, L., Li, Q., Chu, Y., Chao, T., & Wang, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.678194 · Cited by 9
Modeling BCR/ABL-Driven Malignancies in the Mouse
Schneckenleithner, C., Hoelbl‐Kovacic, A., & Sexl, V. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_12 · Cited by 9
Self-citationThe Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation
Heller, G., Nebenfuehr, S., Bellutti, F., Ünal, H., Zojer, M., Scheiblecker, L., Sexl, V., & Kollmann, K. (2020) · iScience · doi:10.1016/j.isci.2020.101602 · Cited by 9
Self-citationCDK6 is essential for mesenchymal stem cell proliferation and adipocyte differentiation
Hu, A. J., Li, W., Pathak, A., Hu, G., Hou, X. S., Farmer, S. R., & Hu, M. G. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1146047 · Cited by 8
Villa, F., Crippa, A., Pelizzoni, D., Ardizzoia, A., Scartabellati, G., Corbetta, C., Cipriani, E., Lavitrano, M., & Ardizzoia, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914427 · Cited by 8
Cdk6: At the interface of Rb and p53
Nebenfuehr, S., Bellutti, F., & Sexl, V. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1511206 · Cited by 8
Self-citationKim, C.-Y., Na, K., Park, S., Jeong, S.-K., Cho, J.-Y., Shin, H., Lee, M. J., Han, G., & Paik, Y. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001456 · Cited by 10
Jurcik, J., Siváková, B., Čipáková, I., Selicky, T., Stupenova, E., Jurcik, M., Osadská, M., Baráth, P., & Čipák, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207637 · Cited by 10
Doma, E., Mayer, I. M., Brandstoetter, T., Maurer, B., Grausenburger, R., Menzl, I., Zojer, M., Hoelbl‐Kovacic, A., Carlsson, L., Heller, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003022 · Cited by 9
Self-citationWang, L., Wang, Y., Zhang, L., Zhao, J., Wu, S., & Yang, Z. (2025) · Molecules · doi:10.3390/molecules30050979 · Cited by 7
Algethami, M., Shoqafi, A., Lashen, A., Alqahtani, S., Spicer, J., Altayyar, A., Tosun, Ç., Jeyapalan, J. N., Mongan, N. P., James, V. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11052-4 · Cited by 7
Woess, K., Macho‐Maschler, S., Schenau, D. V. I., Butler, M., Lassnig, C., Valcanover, D., Poelzl, A., Meissl, K., Maurer, B., Brandstoetter, T., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279848 · Cited by 7
Self-citationAdkins, D. R., Ley, J. C., Cohen, J. A., & Oppelt, P. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000617 · Cited by 8
A C/ebpα isoform specific differentiation program in immortalized myelocytes
García-Cuéllar, M.-P., Akan, S., & Slany, R. K. (2023) · Leukemia · doi:10.1038/s41375-023-01989-8 · Cited by 7
What matters in aging is signaling for responsiveness
Park, S. C., Lee, Y., Cho, K. A., Kim, S. Y., Lee, Y., Lee, S.-R., & Lim, I. K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108560 · Cited by 7
Zheng, M., Zhang, X., Chen, W., Xia, F., Yang, H., Yuan, K., & Yang, P. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0259 · Cited by 7
Gao, M., Sun, L., Liu, Y.-L., Xie, J., Li, Q., Xue, J., Wang, Y.-T., Guo, K.-M., Ma, M., & Li, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.047 · Cited by 7
Parra, M., Baptista, M. J., Genescà, E., Llinàs‐Arias, P., & Esteller, M. (2020) · Hematological Oncology · doi:10.1002/hon.2725 · Cited by 6
Malumbres, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00004-9 · Cited by 10
Self-citationIizumi, Y., Sowa, Y., Goi, W., Aono, Y., Watanabe, M., Kurumida, Y., Kameda, T., Akaji, K., Kitagawa, M., & Sakai, T. (2022) · Communications Biology · doi:10.1038/s42003-022-03522-6 · Cited by 9
Impact of protein and small molecule interactions on kinase conformations
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · eLife · doi:10.7554/elife.94755 · Cited by 6
Self-citationHu, H., Wang, Y., Wang, M., Zhang, Z., Gu, X., Sun, R., Liu, X., Li, N., Ding, N., Li, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01640 · Cited by 6
Lin, H., Cheng, J., Li, R., Zhu, C., Zhao, Y., Yang, Z., Song, G., Huang, Y., Lv, F., Bai, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202516726 · Cited by 6
Ma, B., Gu, C., Lu, R., Lian, P., Wang, W., Huang, Z., Su, Z., & Wang, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113360 · Cited by 6
Cruz, M. R. D. S., Reinert, T., & Cristofanilli, M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.965 · Cited by 6
Węsierska‐Gądek, J., & Mauritz, M. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.155 · Cited by 6
Liu, G., Zhao, H., Ding, Q., Li, H., Liu, T., Yang, H., & Liu, Y. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11879 · Cited by 6
CDK6: an attractive therapeutic target for T-ALL/LBL
Li, W., Hu, J. K., & Hu, M. G. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2285775 · Cited by 5
Xie, J., Wang, W., Wang, N., Dong, Q., Han, H., Feng, Y.-P., Yuan, Y., Feng, J., & Chen, K. (2023) · PubMed Central · Cited by 5
CDK6 3'UTR polymorphisms alter the susceptibility to cervical cancer among Uyghur females
Aierken, K., Dong, Z., Abulimiti, T., Zhang, Y., Abuduxikuer, G., Tuerxun, G., Abudurexiti, G., Maimaitiaishan, A., Mijiti, P., & Abulizi, G. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.626 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
Isabella, S., & Mirunalini, S. (2020) · Breast Cancer · doi:10.1007/s12282-020-01167-z · Cited by 5
Selective CDK6 Degradation via the KLHDC2 E3 Ubiquitin Ligase
Jeon, E., Kim, Y., Ahn, H., Martinez, M. J., Hwang, K., Cho, S., Dwyer, B. G., Romero, B. A., Hinshaw, S. M., Gray, N. S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02713 · Cited by 4
Soluble Guanylate Cyclase β1 Subunit Represses Human Glioblastoma Growth
Xiao, H., Zhu, H., Bögler, O., Mónica, F. Z., Kots, A. Y., Murad, F., & Bian, K. (2023) · Cancers · doi:10.3390/cancers15051567 · Cited by 4
Stupak, E. V., Veryasikina, Y. A., Titov, S. E., Askandaryan, A. S., Hiana, J. C., Zhimulev, I. F., & Stupak, V. V. (2023) · Cureus · doi:10.7759/cureus.35906 · Cited by 3
Agarwal, M., Sharma, A., Kagoo, A., & Bhargava, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-33145-8 · Cited by 4
Steinhart, J., Mӧller, P., Kull, M., Krönke, J., & Barth, T. F. E. (2024) · HemaSphere · doi:10.1002/hem3.32 · Cited by 4
Multiplexed Profiling of CDK Kinase Activities in Tumor Biopsies with Fluorescent Peptide Biosensors
Royet, C., Diot, S., Onofre, M., Lecki, L., Pastore, M., Reynès, C., Lorcy, F., Szablewski, V., Serre, I., & Morris, M. C. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00139 · Cited by 5
Lee, C., Tsai, H.-N., Cheng, E., Lee, T., Lin, P., Lee, M., & Lee, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168658 · Cited by 4
Zhang, D., Xing, Y., Liu, L., Zhang, X., Ma, C., Xu, M., Li, R., Wei, H., Zhao, Y. F., Xu, B., et al. (2025) · Hematology · doi:10.1080/16078454.2025.2456649 · Cited by 4
Groner, B., & Vafaizadeh, V. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.019 · Cited by 4
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer
Sánchez, V. L. C., Criado, J. Á., Martin, V. M., Auñón, P., Arranz, E. E., Ibarguren, A. M., Jiménez‐Nácher, I., & Ambrosio, A. H. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231185855 · Cited by 4
Ning, N., Tian, Z., Feng, H., & Xing, F. (2024) · Medicine · doi:10.1097/md.0000000000040379 · Cited by 3
Palbociclib as an Antitumor Drug: A License to Kill
Łupicka‐Słowik, A., Cossu, F., & Sieńczyk, M. (2024) · Molecules · doi:10.3390/molecules29225334 · Cited by 5
Cdk6’s functions are critically regulated by its unique C-terminus
Schirripa, A., Schöppe, H., Nebenfuehr, S., Zojer, M., Klampfl, T., Kugler, V., Schmalzbauer, B. S., Ceylan, H., Uras, I. Z., Scheiblecker, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111697 · Cited by 3
Self-citationRommelfanger, M. K., Behrends, M., Chen, Y.-L., Martinez, J., Kurella, N., Geisler, N., Guturu, D., Bens, M., Xiong, L., Xiang, Z., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114010 · Cited by 5
FRA1 drives melanoma metastasis through an actionable transcriptional network
Xu, X., Jarajapu, V., Chadourne, M., Soto-Vargas, Z., Ochoa-Rios, S. L., Jasani, N., Wang, K., Mecozzi, N., Yao, J., Yu, X., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03632-5 · Cited by 4
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
Tan, H. N., Curigliano, G., & Yap, T. A. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.03.004 · Cited by 3
Preclinical Studies of PROTACs in Hematological Malignancies
Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3
CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes
Lee, S., Rodriguez, L. R. L., Majumdar, R., de Marval, P. L. M., & Rodríguez‐Puebla, M. L. (2021) · Oncology Letters · doi:10.3892/ol.2021.12993 · Cited by 3
Lee, S. H., Wang, X., Kim, S. H., Kim, Y., & Rodríguez‐Puebla, M. L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6551 · Cited by 3
Tang, C., Lin, L. W., Zhou, W., Liu, X., Fu, Y., Zhang, L., Li, L., Wang, X., Zhao, L., & Liang, J. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.06.06 · Cited by 2
Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?
Wysocki, P. J. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.100128 · Cited by 2
Dual-Input Regulation of β-Cell Proliferation by ATF6α and Glucose via E2F1
Landa-Galván, H. V., CASTRO, T. A., Noel, J. J., Llamas, G. A., Sharma, R. B., & Alonso, L. C. (2025) · Diabetes · doi:10.2337/db25-0279 · Cited by 2
Expression and Significance of Cyclin-Dependent Protein Kinase 6 in Diffuse Large B-Cell Lymphoma
Li, J., Li, P. T., Su, H., Feng, H., Zhongyuan, B., & Xi, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s380496 · Cited by 2
Brett, J. O., Herman, P. E., Mayer, E. L., Bardia, A., & Wander, S. A. (2022) · Current Breast Cancer Reports · doi:10.1007/s12609-022-00461-3 · Cited by 2
Enabling factor for cancer hallmark acquisition: Small nucleolar RNA host gene 17
Zhang, N., Sun, Y., Wang, T., Xu, X., & Cao, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.974939 · Cited by 2
MicroRNA profiling in the malignant progression of gliomas
Stupak, E. V., Veryaskina, Y. A., Titov, S. E., Achmerova, L. G., Stupak, V. V., Ivanov, M., Zhimulev, I. F., & Kolesnikov, N. N. (2016) · AIP conference proceedings · doi:10.1063/1.4960284 · Cited by 2
Stupak, E. V., Veryaskina, Y. A., Titov, S. E., Achmerova, L. G., Stupak, V. V., Dolzhenko, D. A., Rabinovich, S. S., Аркадьевич, Н. А., Ivanov, M., Zhimulev, I. F., et al. (2017) · AIP conference proceedings · doi:10.1063/1.5001652 · Cited by 2
Sun, R., Wang, X., Zhang, L., Gu, Y., Yang, S., Wang, L., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819003 · Cited by 2
Wu, Y., Xu, Z., Kou, Z., Ye, Q., Chen, L., & Gou, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-11043-5 · Cited by 1
Reframing RB Tumor Suppressor Dysfunction as a Therapeutic Vulnerability in Cancer
Malko, R., Shannon, H. E., Dobrota, E. A., Kreklau, K. E., Stevens, L. K., Jackson, K. W., Saadatzadeh, M. R., Pandya, P. H., & Pollok, K. E. (2026) · Cancers · doi:10.3390/cancers18071175 · Cited by 1
CDK6 degradation hits Ph+ ALL hard
Hantschel, O. D. (2020) · Blood · doi:10.1182/blood.2020005136 · Cited by 1
Transduction of miRNA-155 and miRNA-34a in Oral Squamous Cell Carcinoma Cell Line
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.08.026 · Cited by 1
Ushna, S. K., & Das, A. K. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100030 · Cited by 1
Sun, G., Li, Y., Wang, Z., Xu, X., Xiang, Y., Teng, F., Zhao, L., Liu, J., Liu, Z., Xiang, C., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108687 · Cited by 1
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
A cutting-edge approach unravels a novel role for CDK6 in leukemic progenitor cellsPreprint
Doma, E., Mayer, I. M., Brandstoetter, T., Maurer, B., Grausenburger, R., Menzl, I., Zojer, M., Hoelbl‐Kovacic, A., Carlsson, L., Heller, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.05.325886 · Cited by 1
Self-citationMicroRNAs As Biomarkers of Brain TumorsPreprint
Jelski, W., & Mroczko, B. (2024) · Preprints.org · doi:10.20944/preprints202405.0788.v1 · Cited by 1
Kinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · eLife · doi:10.7554/elife.94755.2 · Cited by 1
Self-citationRole of Tat-interacting protein of 110 kDa and microRNAs in the regulation of hematopoiesis
Liu, Y. M., & He, J. J. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000246
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7056
Mira, H., Díez del Corral, R., & Morales, A. V. (2020) · Frontiers research topics · doi:10.3389/978-2-88963-988-5
Fotoohi, S., Radfar, M., Afgar, A., & Harandi, M. F. (2022) · Experimental parasitology · doi:10.1016/j.exppara.2022.108406 · Cited by 1
Data from CDK6 Is a Therapeutic Target in Myelofibrosis
Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2023) · doi:10.1158/0008-5472.c.6513271.v1
A C/ebpα isoform-specific differentiation program in primary myelocytesPreprint
García-Cuéllar, M.-P., Akan, S., & Slany, R. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.16.540903
Kinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.11.575270
Self-citationKinases in motion: impact of protein and small molecule interactions on kinase conformationsPreprint
Kugler, V., Schwaighofer, S., Feichtner, A., Enzler, F., Fleischmann, J., Strich, S. L., Schwarz, S., Wilson, R., Tschaikner, P., Troppmair, J., et al. (2024) · eLife · doi:10.7554/elife.94755.1
Self-citationPROTACs of cyclin-dependent kinases
Veselá, D., Řezníčková, E., Mik, V., & Jorda, R. (2024) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2024.10.003
Ao, M., Wang, X., Cao, Y., Li, X., Zhang, Y.-X., Li, J.-Y., Li, M., Huang, M., Qiu, Y., Hu, H.-Y., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117341
Udden, S. M. N., Jiang, B., Pandey, K., Lewis, C. M., Sahoo, S., Williams, N. S., & Alluri, P. G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687883
ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer
Chen, C., Lee, Y., Huang, Y., Wang, W., & Chang, W. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70113
Sheikh, M. R., Utsha, M. H., Tasnim, J., Alam, M. R., Afrin, U., Chakraborty, A., Rahaman, M. M., Ali, S. M. E., & Sayed, M. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7955881/v1
Ge, X. J., Frank‐Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16442117
Ge, X. J., Frank‐Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16442123
Ge, X. J., Frank‐Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16442141
Ge, X. J., Frank‐Bertoncelj, M., Klein, K., McGovern, A., Kuret, T., Houtman, M., Burja, B., Micheroli, R., Shi, C., Marks, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16442120
Wang, H.-C., Luo, C.-W., Moi, S., Chang, Y.-H., Chang, S., Hung, Y.-H., Chen, T.-Y., Chen, Y.-Z., Lai, C.-Y., Yang, Y.-C., et al. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105024
Kawamoto, Y., Yamaguchi, A., Ma, X., Fu, Y., Guo, Q., Uemura, M., Fujino, H., & Maeshige, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38076-8
CMGC Kinases in Viral Infection and Human Disease
Amusan, O. T., & Guo, H.-Y. (2026) · Pathogens · doi:10.3390/pathogens15040366
Metadata
- Authors
- Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., Reichart, U., Mayerhofer, M., Hoeller, C., Zöchbauer-Müller, S., Kerjaschki, D., Bock, C., Kenner, L., Hoefler, G., Freissmuth, M., Green, A. R., Moriggl, R., Busslinger, M., Malumbres, M., & Sexl, V.
- Affiliations
- University of Veterinary Medicine Vienna (AT)
- Comprehensive Cancer Center Vienna (AT)
- Research Institute of Molecular Pathology (AT)
- Medical University of Vienna (AT)
- Austrian Academy of Sciences (AT)
- Ludwig Boltzmann Institute for Cancer Research (AT)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Sexl, Veronika
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 24
- Issue
- 2
- Pages
- 167-181
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC5637299
- OpenAlex
- W2152600133
- Cited by
- 313
- References
- 81
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 27 · 2023: 23 · 2022: 35 · 2021: 33 · 2020: 42 · 2019: 25 · 2018: 20 · 2017: 20 · 2016: 17 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-08-08)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (079249, 100140)
- Medizinische Universität Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- CDK6, CDK4, p16INK4a, VEGF-A, tumor angiogenesis, B-cell acute lymphoblastic leukemia, BCR-ABL, transcriptional regulation, cell cycle, kinase-independent function, lymphoid malignancies, cell proliferation, hematologic malignancies
- MeSH terms
- Animals, Cell Cycle, Humans, Mice, Inbred C57BL, Mice, Nude, Mice, Transgenic, Neoplasms, Neovascularization, Pathologic, Leukemia, B-Cell, Lymphoma, B-Cell, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
